ALAMEDA, Calif.--(BUSINESS WIRE)--InSite Vision Incorporated (OTCBB: INSV), a company developing ophthalmic products for unmet eye care needs, today announced plans to advance new development candidate ISV-303, a topical anti-inflammatory product intended to reduce the pain and swelling associated with ocular surgery. InSite Vision formulated a lower concentration of bromfenac with its proprietary DuraSite® technology to create a proprietary therapeutic product. InSite Vision intends to advance ISV-303 into clinical studies pending the completion of Investigational New Drug-enabling toxicology studies in the first half of 2010.
